Jeremy Phillip Harris

Picture of Jeremy Phillip Harris
Assistant Professor of Clinical Radiation Oncology, Radiation Oncology
School of Medicine
M.D., Stanford University, 2014
M.Phil., Cambridge University, 2009, Chemistry
B.S., Johns Hopkins University, 2008, Chemical and Biomolecular Engineering
Phone: (714)456-5651
University of California, Irvine
101 The City Dr S
Building 23
Orange, CA 92868
Research Interests
lung cancer, non-small-cell lung cancer, sarcoma, spine tumors, radiation therapy, stereotactic body radiation therapy (SBRT), radiosurgery (SRS), health services research, cost effectiveness research, patient reported outcomes
Research Abstract
Dr. Harris's clinical research interests involve the treatment of lung cancer, sarcomas, and spine tumors. His endeavors are focused on the combination of newer radiation treatment techniques/technologies with systemic therapies and ablative therapies in order to improve the efficacy of cancer treatment and reduce side effects. As a faculty member at UC Irvine, Dr. Harris has received funding for his investigator-initiated trials focusing on novel treatments of lung tumors as well as sarcomas.

His health services research interests are in health-related quality of life, financial toxicity, cost analysis, and comparative effectiveness analysis with large claims-based databases.
Short Biography
Dr. Harris is a clinician-investigator at UC Irvine with primary clinical interests in lung cancer, sarcoma, spine tumors, and head and neck cancers. Dr. Harris has been the Director of Thoracic Radiation Oncology since 2019.

After graduating from Johns Hopkins University with a Bachelors of Science in Chemical and Biomolecular Engineering, he completed a Masters degree in Chemistry at Cambridge University with funding through the Churchill Scholarship Foundation. Thereafter, Dr. Harris completed medical school training at Stanford University. His Radiation Oncology training was at Stanford University, where he conducted clinical research and developed expertise in health services and cost-effectiveness methodologies.
1. Trakul N, Chang CN, Harris JP, Chapman C, Rao A, Shen J, Quinlan-Davidson S, Filion EJ, Wakelee HA, Colevas AD, Whyte RI, Dieterich S, Maxim PG, Hristov D, Tran P, Le QT, Loo BW, Diehn M. Tumor Volume-Adapted Dosing in Stereotactic Ablative Radiotherapy of Lung Tumors. Int J Radiat Oncol Biol Phys, 2012. 84(1):231-7. PMID: 22381907.

2. Trakul N, Harris JP, Le QT, Hara WY, Maxim PG, Loo BW, Diehn M. Stereotactic ablative radiotherapy for reirradiation of locally recurrent lung tumors. J Thorac Oncol, 2012. 7(9):1462-5. PMID: 22895143.

3. Hiniker SM, Roux A, Murphy JD, Harris JP, Tran PT, Kapp DS, Kidd EA. Primary Squamous Cell Carcinoma of the Vagina: Prognostic Factors, Treatment Patterns, and Outcomes. Gynecologic Oncology, 2013. 131(2):380-5. PMID: 23954572.

4. Harris JP, JD Murphy, AL Hanlon, Le QT, Loo BW, Diehn M. A population-based comparative effectiveness study of radiation therapy techniques in stage III non-small-cell lung cancer. Int J Radiat Oncol Biol Phys, 2014. 88(4):872-84. PMID: 24495591.

5. Hiniker SM, Agarwal R, Modlin LA, Gray CC, Harris JP, Million L, Kiamanesh EF, Donaldson SS. Survival and Neurocognitive Outcomes Following Cranial or Craniospinal Irradiation Plus Total Body Irradiation Prior to Stem Cell Transplantation in Pediatric Leukemia Patients with Central Nervous System Involvement. Int J Radiat Oncol Biol Phys, 2014. 89(1):67-74. PMID: 24725690.

6. Harris JP, Chang-Halpenny CN, Maxim PG, Quon A, Graves EE, Diehn M, Loo BW. Outcomes of modestly hypofractionated radiation for lung tumors: pre- and mid-treatment positron emission tomography-computed tomography metrics as prognostic factors. Clinical Lung Cancer, 2015. 16(6):475-85. PMID: 25770888.

7. Gentles AJ, Bratman SV, Lee LJ, Harris JP, Feng W, Nair RV, Shultz DB, Nair VS, Hoang CD, West RB, Plevritis SK, Alizadeh AA, Diehn M. Integrating Tumor and Stromal Gene Expression Signatures With Clinical Indices for Survival Stratification of Early-Stage Non-Small Cell Lung Cancer. JNCI, 2015. 107(10):1-11. PMID: 26286589.

8. Hiniker SM, Modlin LA, Choi CY, Atalar B, Seiger K, Binkley MS, Harris JP, Liao YJ, Fischbein N, Wang L, Ho A, Lo A, Chang SD, Harsh GR, Gibbs IC, Hancock SL, Li G, Soltys SG. Dose-Response Modeling of the Visual Pathway Tolerance to Single-Fraction and Hypofractionated Stereotactic Radiosurgery. Semin Radiat Oncol, 2016. 26(2):97-104. PMID: 27000505.

9. Chen M, Harris JP, Hara W, Sirjani D, Divi V. Association of Postoperative Radiotherapy With Survival in Patients With N1 Oral Cavity and Oropharyngeal Squamous Cell Carcinoma. JAMA Otolaryngology-Head & Neck Surgery, 2016. 142(12):1224-1230. PMID: 27832255.

10. Pollom E, Wang G, Harris JP, Koong AC, Bendavid E, Bhattacharya J, Chang DT. The Impact of Intensity Modulated Radiation Therapy on Hospitalization Outcomes in the SEER-Medicare Population With Anal Squamous Cell Carcinoma. Int J Radiat Oncol Biol Phys. 2017. 98(1):177-185. PMID: 28258896.

11. Chen JJ, Shah JL, Harris JP, Bui TT, Schaberg K, Kong C, Kaplan M, Divi V, Schoppy D, Le QT, Hara W. Clinical outcomes of elderly patients treated for oral cavity squamous cell carcinoma. Int J Radiat Oncol Biol Phys, 2017. 98(4):775-783. PMID: 28602409.

12. Harris JP, Patel MI, Loo BW, Wakelee HA, Diehn M. A Population-Based Comparative Effectiveness Study of Chemoradiation Regimens in Stage III Non-Small Cell Lung Cancer. Lung Cancer, 2017. 108:173-182. PMID: 28625632.

13. Chen MM, Orosco RK, Harris JP, Porters JP, Rosenthal EL, Hara W, Sirjani D, Divi V. Predictors of Readmissions after Head and Neck Cancer Surgery: A National Perspective. Oral Oncology, 2017. 71:106-112. PMID: 28688676.

14. Qian Y, Maruyama S, Kim H, Pollom EL, Kumar KA, Chin AL, Harris JP, Chang DT, Pitt A, Bendavid E, Owens DK, Durkee BY, Soltys SG. Cost-Effectiveness of Radiation and Chemotherapy for High-Risk Low-Grade Glioma. Neuro-Oncology, 2017. 19(12):1651-1660. PMID: 28666368.

15. Pollom EL, Fujimoto DK, Han SS, Harris JP, Tharin SA, Soltys SG. Newly Diagnosed Glioblastoma: Adverse Socioeconomic Factors Correlate with Delay in Radiotherapy Initiation and Worse Overall Survival. Journal of Radiation Research, 2018. 59(supp 1):i11-i18. PMID: 29432548.

16. Harris JP, Chen MM, Orosco RK, Sirjani D, Divi V, Hara W. Association of Survival With Shorter Time to Radiation Therapy After Surgery for US Patients With Head and Neck Cancer. JAMA Otolaryngology—Head and Neck Surgery, 2018. 144(4):349-359. PMID: 29522072.

17. Chen MM, Harris JP, Orosco RK, Sirjani D, Hara W, Divi V. The Association of Time between Surgery and Adjuvant Therapy with Survival in Oral Cavity Cancer. Otolaryngology-Head and Neck Surgery. 2018. Jan 9. PMID: 29313448.

18. Harris JP, Nwachukwu C, Qian Y, Pollom E, Loo BW, Das M, Diehn M. Invasive Nodal Evaluation Prior to Stereotactic Ablative Radiation for Non-Small Cell Lung Cancer. Lung Cancer, 2018. 124:76-85. PMID: 30268484.

19. Chen JJ, Harris JP, Kong C, Sunwoo JB, Divi V, Horst KC, Aasi SZ, Hollmig ST, Hara W. Clinical perineural invasion of cutaneous head and neck cancer: Impact of radiotherapy, imaging, and nerve growth factor receptors on symptom control and prognosis. Oral Oncology, 2018. 85:60-67. PMID: 30220321.

20. Harris JP, Saraswathula A, Kaplun B, Qian Y, Chan KCA, Chan ATC, Le QT, Owens DK, Goldhaber-Fiebert JD, Pollom E. Cost-Effectiveness of Screening for Nasopharyngeal Carcinoma for Asian-American Men in the US. Otolaryngology-Head and Neck Surgery, 2019. Jul. 161(1):82-90. PMID: 30832545.

21. Koenig JL, Toesca DAS, Harris JP, Tsai J, Haraldsdottir S, Lin AY, Pollom EL, Chang DT. Microsatellite Instability and Adjuvant Chemotherapy in Stage II Colon Cancer. Am J Clin Oncol, 2019. 2019, Jul. 42(7):573-580. PMID: 31166206.

22. Nwachukwu CR, Harris JP, Chin A, Von Eyben R, Giaretta S, Shaffer JL, Hiniker SM, Kapp DS, Folkins AK, Kidd EA. Prognostic Significance of P16 Expression and P53 Expression in Primary Vaginal Cancer. Int J Gynecol Pathol, 2019. Nov. 38(6):588-596. PMID: 31593028.

23. Jin MC, Harris JP, Sabolch AN, Gensheimer M, Le QT, Beadle BM, Pollom EL. Proton Radiotherapy and Treatment Delay in Head and Neck Squamous Cell Carcinoma. The Laryngoscope, 2019. Dec. 14. PMID: 31837165.

24. Harris JP, Kashyap M, Humphreys JN, Chang DT, Pollom EL. The Clinical and Financial Cost of Mental Disorders Among Elderly Patients with Gastrointestinal Malignancies. Cancer Medicine, 2020. Oct 6. PMID: 33022135.

25. Harris JP, Kashyap M, Humphreys JN, Chang DT, Pollom EL. Longitudinal Analysis of Mental Disorders Among Elderly Patients with Gastrointestinal Malignancies. JNCCN, 2021. Jan 5. PMID: 33401234.

26. Goshtasbi K, Lehrich BM, Birkenbeuel JL, Abiri A, Harris JP, Kuan EC. A Comprehensive Analysis of Treatment Management and Survival Outcomes in Nasopharyngeal Carcinoma. Otolaryngology-Head and Neck Surgery, 2020. Nov 24. PMID: 33231508.

27. Kashyap M, Harris JP, Chang DT, Pollom EL. Impact of Mental Illness on End-of-Life Emergency Department Use in Elderly Patients with Gastrointestinal Malignancies. Cancer Medicine, 2021. Mar. 10(6):2035-2044. PMID: 33621438.

28. Abiri A, Yasaka TM, Lehrich BM, Goshtasbi K, Papagiannopoulos P, Tajudeen B, St John M, Harris JP, Kuan EC. Adjuvant Therapy and Prognosticators of Survival in Head and Neck Mucosal Melanoma. The Laryngoscope, 2021. Aug 6. PMID: 34355791.

29. Riviere P, Brazel D, Goshtasbi K, Kuan EC, Gao L, Harris JP. Comorbid Immunosuppression in Merkel Cell Carcinoma, a Retrospective Database Study. Journal of American Academy of Dermatology International, 2021. Accepted.

30. Yeakel J, Kannan A, Rattigan NH, Yamamoto M, Aleshin A, Harris JP, Gao L. Bespoke circulating tumor DNA as a biomarker for treatment response in a refractory Merkel cell carcinoma patient. Journal of the American Academy of Dermatology Case Reports, 2021. Oct. 18:94-98. PMID: 34869814.

31. Sodji QH, Harris JP, Quon A, Modlin LA, Carter JN, Lau B, Jian A, Trakul N, Maxim PG, Diehn M, Hiniker SM, Loo BW. Detection of Recurrence after Thoracic Stereotactic Ablative Radiotherapy Using FDG-PET-CT. Clinical Lung Cancer, 2022. Accepted.

32. Harris JP, Fujimoto DK, Nagasaka M, Ku E, Harada G, Keshava H, Mahtabifard A, Longoria J, Patel N, Seyedin S, Simon A, Chen A. Controversies in lung cancer: heterogeneity in treatment recommendations for stage III NSCLC according to disease burden and oncogenic driver alterations. Clinical Lung Cancer, 2022. Accepted.
<ul> <li>2021-2023. UCI Chao Family Comprehensive Cancer Center Anti-Cancer Grant. Role: PI. "A pilot study of immunotherapy combined with stereotactic ablative radiotherapy for patients with advanced or metastatic sarcoma".</li> <li>2022. Pilot Project Grant from the American Cancer Society Institutional Research Grant. Role: PI. "A novel method for treating lung tumors with the combination of electrical fields and radiation therapy: a pilot study".</li> </ul>
Professional Societies
International Association for the Study of Lung Cancer
SWOG Cancer Research Network
Graduate Programs
Radiation Oncology
Research Centers
Last updated